Skip to content
DataLookout
Menu

PHMNCT05850936

Effect of IOP Lowering on Progressive HM

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 3 to 11
    • Publications: details revised at 3 of 4 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Sep 30, 2026 to Nov 20, 2026
    • Study completion date: Sep 30, 2028 to Nov 30, 2028
    • Site details revised
    v4
  3. Notable Primary completion date: Apr 30, 2025 to Sep 30, 2026
    • Study completion date: Apr 30, 2025 to Sep 30, 2028
    • Secondary endpoints: 4 to 3
    • Publications: details revised at 2 of 4 entries
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 7, 2023 to Jun 1, 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized change in axial length (AL) from baseline to 12 months
Timeframe: 12 months

Secondary (11)

Annualized change in axial length (AL) from baseline to 24 months
Annualized change in axial length (AL) from baseline to 36 months
Change in spherical equivalent (SE) from baseline
Change in intraocular pressure (IOP) from baseline
Change in choroidal thickness (ChT) from baseline
Show 6 moreShow less
Change in visual field (VF) parameters and incidence/progression of VF defects
Change in retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness
Change in retinal and choroidal vascular parameters measured by OCTA
Incidence of optic nerve head morphological changes
Incidence and progression of myopic maculopathy (MMD)
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

Arms and interventions

Intervention armExperimental

medical reduction of IOP by eyedrops

control armNo intervention

follow up without medication

Drugs: Assigned Interventions: IOP-lowering eye drops

Sites

1 site in 1 country

  • Zhongshan Ophthalmic Center, Sun Yat-sen UniversityGuangzhou, Guangdong, China